TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05299788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active external warming
Description: In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice application
Description: In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
Study: NCT02573038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
Study: NCT01483586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kanglaite gelcap
Description: 3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite gelcap
Description: 6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
Study: NCT04149392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
Study: NCT04440371

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly
Description: Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly
Description: Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol/Betamethasone ointment plus NBUVB
Description: Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol/Betamethasone ointment plus NBUVB
Description: Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
Study: NCT02761629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon Alpha-2A
Description: Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon Alpha-2A
Description: Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.
Study: NCT03048110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 (ODM-201)
Description: In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
Study: NCT01694992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
Study: NCT00654693

Intervention type: OTHER
Intervention: Rapid Response Team
Description: If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
Study: NCT00749619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter Lock Solution Taurolidine and Citrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter Lock Solution :Taurolidine and Citrate and Heparin

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Catheter Lock Solution : Heparin
Study: NCT02684318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib
Study: NCT01370811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin and clonidine oral solution treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin and clonidine oral solution treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin and clonidine oral solution treatment C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxybutynin and clonidine oral solution treatment D
Description: Placebo
Study: NCT04068818

Intervention type: DEVICE
Intervention: ANTERION
Description: Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center

Intervention type: DEVICE
Intervention: ANTERION
Description: Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
Study: NCT01285713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Dextrose (D5) in Normal Saline (NS)
Description: D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline (NS)
Description: NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
Study: NCT02451358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative
Description: 0.25 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative
Description: 0.5 mL, Intramuscular
Study: NCT03100019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Study: NCT02684318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib
Study: NCT03037008

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal Sonography
Description: In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal Sonography
Description: In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
Study: NCT04180423

Intervention type: DEVICE
Intervention: Off-the-Shelf Implant Total Knee Replacement
Description: Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
Study: NCT03193905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bairhugger Full Access Underbody Blanket
Description: 30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
Study: NCT04180423

Intervention type: DEVICE
Intervention: Customized Implant Total Knee Replacement
Description: Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
Study: NCT03193905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cotton blanket - control group
Description: 30 patients undergo standard procedure with a cotton blanket
Study: NCT00782080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedariston
Description: St. John´s Wort (100 mg) Valerian Extract (50 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02400112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin powder administered locally, intraoperatively at site of open fracture
Study: NCT00435539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Intravitreal sham injection
Study: NCT03047460

Intervention type: OTHER
Intervention: multimodal evoked potentials
Study: NCT02926196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010718C
Description: MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
Study: NCT00231465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere®)
Description: Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: ZD1839 will be continued until progression, or until trial closure, whichever comes first.
Study: NCT01596244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic
Description: Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
Study: NCT03003897

Intervention type: OTHER
Intervention: Soluble Fiber
Description: Participants receiving soluble fiber.
Study: NCT01894282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy Arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy Arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mind Body Intervention
Description: Combination of manual therapy and cognitive behavioral therapy for pain.
Study: NCT01462292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 3mg/kg/week
Description: Comparison of 2 doses of GSK2402968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 6 mg/kg/week
Description: Comparison of 2 doses of GSK2402968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK2402968 3 mg/kg/week
Description: Matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK2402968 6 mg/kg/week
Description: Matched Placebo
Study: NCT03145129

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure
Study: NCT00510692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentanoic Acid (EPA)
Description: 2 x 500mg EPA capsules twice daily for 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy with video and photographs at baseline and month 6.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: Endoscopy with video and photographs at baseline and month 6.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies taken
Description: 9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
Study: NCT03003897

Intervention type: OTHER
Intervention: Placebo
Description: Participants receiving placebo.
Study: NCT03563612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cpap
Description: application of cpap to the non-dependent lung, during one lung ventilation
Study: NCT00510692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 500mg placebo capsules twice daily for 6 months
Study: NCT01804361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haporine-S
Description: 1 or 2 drops twice a day at 12 hour interval for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis (cyclosporine 0.05%)
Description: 1 or 2 drops twice a day at 12 hour interval for 12 weeks
Study: NCT03591952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction-Driven Thoracentesis
Description: Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gravity-Driven Thoracentesis
Description: Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
Study: NCT02684318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib
Study: NCT00997685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin
Description: Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles
Study: NCT02973815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NU-HOME Intervention
Description: The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
Study: NCT00907725

Intervention type: OTHER
Group type: OTHER
Intervention: serum BhCG follow-up
Description: Subjects in this arm will receive medical abortion follow-up using BhCG blood draw

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasonographic follow-up
Description: Subjects in this arm will receive medical abortion follow-up by ultrasound
Study: NCT04624932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RR Digital Tool
Description: This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Position Statement on Active Outdoor Play
Description: This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
Study: NCT04341753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry.
Study: NCT01563146

Intervention type: OTHER
Intervention: Data collection
Description: Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
Study: NCT02599948

Intervention type: OTHER
Intervention: no intervention
Study: NCT01452425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOS assessment
Description: Near Infraread spectroscopy, non invasive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG assessment
Description: Electromyography, non invasive
Study: NCT03799120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin BID
Description: comparison of once daily versus twice daily tamsulosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin BID
Description: comparison of once daily versus twice daily tamsulosin
Study: NCT01962636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
Study: NCT03799120

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00666341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
Study: NCT01962636

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.